Bayer, BASF in Talks for Vegetable Seeds Business Sell-Off

Bayer AG BAYRY announced that it is in exclusive talks with BASF for the divestiture of its entire vegetable seeds business. The seed businesses which are to be divested include the global cotton seed business (excluding India and South Africa), the canola business in North America and Europe, and the soybean seed business. Through this move, Bayer intends to address the concerns of European Union.

Notably, the company intends to divest these assets as part of its strategy to complete the planned acquisition of Monsanto Co. MON .

So far this year, Bayer's shares have underperformed the industry. The stock has declined 8.1% compared with the industry 's gain of 8.9%.

In October 2017, the company inked a deal to sell selected Crop Science businesses to BASF for €5.9 billion. Per the deal, the assets to be divested include Bayer's global glufosinate-ammonium non-selective herbicide business and the related LibertyLink technology for herbicide tolerance as well as its seed businesses for key row crops in select markets.

The transaction includes respective research and development capabilities as well. In 2017, revenues from these businesses amounted to around €1.6 billion.

In September 2016, Bayer signed a definitive merger agreement to acquire United States' seed giant Monsanto in a deal worth approximately $66 billion. The combined business is expected to boost Bayer's Crop Science business and provide accretion to its core earnings from the first full year of the closing of the transaction, followed by double-digit percentage growth.

The divestiture is subject to the closure of Monsanto deal and Bayer is working with the relevant authorities to end the acquisition by second quarter of 2018. The European Commission recently extended the examination deadline for the acquisition until Apr 5, 2018. In fact, the company plans to utilize the net proceeds from the divestiture for partially refinancing the planned acquisition of Monsanto.

Bayer Aktiengesellschaft Price

Bayer Aktiengesellschaft Price | Bayer Aktiengesellschaft Quote

Zacks Rank & Stocks to Consider

Bayer carries a Zacks Rank #4 (Sell).

A few better-ranked stocks from the same space are Regeneron REGN and Ligand Pharmaceuticals LGND . Both Regeneron and Ligand sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

Regeneron's earnings per share estimates have moved up from $17.13 to $18.65 and from $20.37 to $21.56 for 2018 and 2019, respectively in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.

Ligand's earnings per share estimates have moved up $3.54 to $4.15 from $4.75 to $5.75 for 2018 and 2019, respectively, over the last 30 days. The company delivered positive earnings surprises in three of the trailing four quarters, with an average beat of 24.88%. The company's shares have rallied 57.2% over a year.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report

Monsanto Company (MON): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More